A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

Type of Cancer
Gynecologic

Sponsor
Genentech & GOG

Protocol Number
Genentech GOG YO39523/GOG3015

To Learn More Call
(201)-510-0950